drugset / Trial / NCT05498467
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis
RandomizedParallel-groupDouble-blindTreatment
Summary
The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy
Timeline
- Start
- 2022-10-11
- Primary completion
- 2023-12-01
- Completion
- 2024-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Anakinra | Protein / enzyme biologic | 100 mg | Subcutaneous |